Enlivex rises on regulatory clearance for changes to sepsis therapy trial

Enlivex

24/08/2022 17:08

** U.S.-listed shares of Enlivex Therapeutics Ltd  ENLV.O 
rise 5.5% to $5.57 
    ** Says regulatory authorities in Israel, Spain and Greece
have cleared certain amendments to co's mid-stage trial design
evaluating its cell therapy Allocetra in patients with sepsis
 urn:newsml:reuters.com:*:nGNX6PDB4Y
    ** Changes will enable treatment of newly enrolled patients
with frozen Allocetra formulation, allow expansion of study
population
    ** Co plans to submit the same amendments to more regulators
    ** Expects that acceptance of the proposed amendments will
shorten timeline for potential regulatory approval of frozen
Allocetra formulation in sepsis, and its commercial launch
    ** Including session's gain, stock down ~11% YTD

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))